Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Blogger Daniel Zeller’s discussion includes classifying cancer as metastatic, starting ADT and testing testosterone levels
Understanding the pros and cons of different treatments may help men and their health care teams make more informed treatment decisions.
I don’t think I’ve ever been so frustrated by “good” news about my prostate cancer, writes blogger Daniel Zeller.
Participating in clinical trials for his metastatic prostate cancer, Drew Bouton has helped define the standard of care.
Chicago Cubs second baseman Ryne Sandberg retired in 1997. He is undergoing treatment for prostate cancer.
People who received Pluvicto reported improved quality of life, including less pain.
A UCSF trial tests precision radiation with immunotherapy as new treatment for advanced cases of metastatic prostate cancer.
The radiopharmaceutical doubled progression-free survival time from six to 12 months.
New research links mutations in an RNA region that helps regulate protein production to progression and drug resistance.
American Cancer Society stresses the need for early detection, screening and prevention strategies, especially for at-risk communities.
Patients taking the combination with prednisone saw an improvement in progression-free survival.
The approval makes Talzenna (talazoparib) the third PARP-blocking drug to be cleared by the FDA to treat prostate cancer.
Plus: NCCN calls for solutions to the shortage that’s affecting common treatments for breast, blood, lung and prostate cancers.
Andy Taylor, Tim Commerford, Jamie Raskin and Martina Navratilova make cancer headlines.
Drugs developed to target particular genetic changes may not be right for every person whose cancer shows those alterations or mutations.
How Duran Duran’s Andy Taylor inspired Rage Against the Machine’s Tim Commerford to disclose his own battle with prostate cancer
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.